OncoMatch/Clinical Trials/NCT06510283
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Is NCT06510283 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Taitacept for anti-n-methyl-d-aspartate receptor encephalitis.
Treatment: Taitacept — The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis. Through this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: GRIN1 anti-NMDAR (GluN1) IgG antibody detected in CSF
Positive anti-NMDAR (GluN1) IgG antibody detected in CSF
Required: LGI1 antibody detected in serum and/or CSF
positive serum and/or cerebrospinal fluid LGI1 antibody
Prior therapy
Must have received: steroids and rituximab or other immunosuppressants (steroids, rituximab, azathioprine, mycophenolate mofetil, cyclophosphamide)
Refractory AE: ineffective treatment with steroids and rituximab or other immunosuppressants, post-treatment mRS score≥2 (stable for at least 24 hours); Recurrent AE: at least 2 months after 1st or 2nd line treatment, new symptoms or worsening of existing symptoms (mRS increase>1)
Cannot have received: biological therapies (rituximab)
Received rituximab or other biological therapies within 1 month prior to enrollment
Lab requirements
Blood counts
white blood cell count<3×10^9 /l, neutrophil count<1.5×10^9 /l, hemoglobin<85g/l, blood platelet count<80×10^9 /l
Kidney function
serum creatinine>1.5×uln
Liver function
tbil(total bilirubin) >1.5×uln, alt>3× uln, ast>3× uln, alkaline phosphatase>2× uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify